BiotechTube
Magle Biopharma

Magle Biopharma

Malmö, Sweden· Est.
maglebiopharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Magle Biopharma is a stem cell-focused CDMO based in Malmö, Sweden, founded in 2017. It offers end-to-end services for the development and GMP manufacturing of cell therapies, catering to biotech and pharmaceutical clients. The company leverages its expertise and facilities to accelerate the translation of stem cell innovations into clinical and commercial products. Its business model is entirely service-based, positioning it as a critical enabler in the advanced therapy medicinal products (ATMP) sector.

OncologySmall Molecules

Technology Platform

Stem cell therapy development and GMP manufacturing platform, offering integrated services from process/analytical development to fill-finish for cellular products.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

High growth in the cell therapy CDMO market creates strong demand for specialized manufacturing partners.
A focused expertise in stem cells allows it to capture a valuable niche and build a reputation for quality in a supply-constrained sector.
Its European base is advantageous for clients targeting EMA regulatory approval.

Risk Factors

Revenue is entirely dependent on the clinical and financial success of client companies, creating high volatility.
Faces intense competition from larger, well-capitalized CDMOs.
Operational and quality control failures could be catastrophic for its business reputation.

Competitive Landscape

Competes with large, diversified CDMOs (e.g., Lonza, Catalent) and other niche cell therapy CDMOs. Differentiation is based on deep specialization in stem cells, integrated service offerings, and a focus on European regulatory pathways. Must compete on quality, reliability, and technical expertise rather than scale.

More companies in Sweden →